4G/5G Polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting

American Heart Journal

Volumn 146, Issue 5, 2003, Pages 855-861

  Böttiger, Corinna ^a,b   Koch, Werner ^a   Lahn, Christina ^a   Mehilli, Julinda ^a   Von Beckerath, Nicolas ^a   Schömig, Albert ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL INJURY; CORONARY ARTERY DISEASE; CORONARY STENT; DEATH; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RESTENOSIS; REVASCULARIZATION; RISK FACTOR; THROMBOSIS; TREATMENT OUTCOME; WOUND HEALING;

EID: 0242468104     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00363-6     Document Type: Article

References (46)

1. Kastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. JACC 1997;30:1428-36.
2. Kohler HP, Grant PJ. Plasminogen activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-801.
3. Huber K, Jörg M, Probst P, et al. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992;67:209-13.
4. Sakata K, Miura F, Sugino H, et al. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996;131:1-6.
5. Ishiwata S, Tukada T, Nakanishi S, et al. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 1997;133:387-92.
6. Strauss BH, Lau HK, Bowman KA, et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 1999;100:1616-22.
7. Fornitz GG, Nielsen P, Amtorp O, et al. Impaired fibrinolysis determines the outcome of percutaneus transluminal coronary angioplasty (PTCA). Eur J Clin Invest 2001;31:586-92.
8. Ortlepp JR, Hoffmann R, Killian A, et al. The 4G/5G promotor polymorphism of the plasminogen activator inhibitor-1 gene and late lumen loss after coronary stent placement in smoking and non-smoking patients. Clin Cardiol 2001;24:585-91.
9. Prisco D, Fedi S, Antonucci E, et al. Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 2001;104:181-6.
10. Carmeliet P, Moons L, Lijnen R, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997;96:3180-91.
11. Hasenstab D, Forough R, Clowes AW. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinase-2 increase after arterial injury in rats. Circ Res 1997;80:490-6.
12. Kjøller L, Kanse SM, Kirkegaard T, et al. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997;232:420-9.
13. DeYoung MB, Tom C, Dichek DA. Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation 2001;104:1972-7.
14. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-45.
15. Eriksson P, Kallin B, van't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-5.
16. Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995;74:837-41.
17. Ossei-Gerning N, Mansfield MW, Stickland MH, et al. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 1997;17:33-7.
18. Schömig A, Kastrati A, Mudra H, et al. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation 1994;90:2716-24.
19. Schömig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
20. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999;14:143-9.
21. Margaglione M, Grandone E, Cappucci G, et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997;77:605-6.
22. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 1990;82:1193-202.
23. Rutherford JD, Braunwald E, Cohn PF. Chronic ischemic heart disease. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. 3rd ed. Philadelphia: WB Saunders Company; 1988. p. 1314-78.
24. World Health Organization Study Group. Diabetes mellitus. WHO Tech Rep Ser 1985;727:1-104.
25. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-83.
26. Simpson AJ, Gray RS, Moore NR, et al. The effects of chronic smoking on fibrinolytic potential of plasma and platelets. Br J Haematol 1997;97:201-13.
27. Hughes K, Choo M, Kuperan P, et al. Cardiovascular risk factors in relation to cigarette smoking: a population-based survey among Asians in Singapore. Atherosclerosis 1998;137:253-8.
28. Eren M, Painter CA, Atkinson JB, et al. Age-dependent spontaneous arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002;106:491-6.
29. Held C, Hjemdahl P, Rehnqvist N, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris and treated with verapamil and metoprolol. Circulation 1997;95: 2380-6.
30. Thögersen AM, Jansson J-H, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation 1998;98:2241-7.
31. Iwai N, Shimoike H, Nakamura Y, et al. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 1998;136:109-14.
32. Margaglione M, Cappucci G, Colaizzo D, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998;1: 152-6.
33. Gardemann A, Lohre J, Katz N, et al. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999;82:1121-6.
34. Ridker PM, Charles HH, Lindpaintner K, et al. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promotor of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62.
35. Anderson JL, Muhlestein JB, Habashi J, et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol 1999;34:1778-83.
36. Doggen CJ, Bertina RM, Cats VM, et al. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 1999;82:115-20.
37. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999;10:499-510.
38. Xiaoli M, Wenying H, Mingpeng S. Effects and mechanism of tissue-type plasminogen activator and plasminogen activator inhibitor on vascular smooth muscle cell proliferation. Int J Cardiol 1998;66(1 Suppl):S57-64.
39. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Ann Rev Cell Biol 1988;4:93-126.
40. Chandler WL, Trimble SL, Loo SC, et al. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 1990;76:930-7.
41. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989;79:101-6.
42. Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT study group: European concerted action on thrombosis and disabilities. Circulation 1996;94:2057-63.
43. Iacoviello L, Burzotta F, Di Castelnuovo A, et al. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998;80:1929-30.
44. A polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999;99:1005-10.
45. Koch W, Böttiger C, Mehilli J, et al. Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. Am J Cardiol 2001;88:1120-4.
46. Henry M, Tregouët DA, Alessi MC, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol 1998;18:84-9.